When Amonkhet spoiled, Vizier of Remedies sparked interest among Modern players as a possible redundancy boost to Abzan Company, the grandchild of beloved Modern archetype pillar Birthing Pod. It's been nearly a month now since the set was released to Modern, and Vizier seems to have succeeded in improving Abzan Company... as well...

The Legacy metagame was thrown on its head after the banning of Sensei's Divining Top, and many cards have benefited from the change...

DJ advises today on some cards to watch for while picking bulk – seemingly useless cards can add up to big money if you know what to look for.

Last week, an old Magic buddy texted me out of the blue, asking if I was interested in going to SCG Baltimore at the end of the month to play some live Modern. My first reaction: “Can’t do it, I’ve got way too much going on…” But then I...

Today, Mike breaks down some of the most successful and innovative decks of Pro Tour Amonkhet and their implications for the marketplace.

Matthew Lewis presents the MTGO Market Report for this week, evaluating important events in the online market and highlighting a “trade of the week.”

I'm back this week with more of my popular financial set review, now tackling the Modern Masters 2017 rares. I won't cover each rare in the set, but I will review the most important ones in depth. I also want to talk about a few choice uncommons, so grab your calendars and wallets. You'll...

Two clear winners emerged at PT Amonkhet in Zombies and Marvel. Brian discusses where prices will be moving presently, and which cards are most affected.

Diego's back with a graphic visualization of Pro Tour Amonkhet.

Tilt is quite a mighty thing. Re-reading my fevered scrawlings from last week proved deeply concerning. I knew I was unwell, but I didn't know how unwell. While I'm better now, I may need to refocus before things get worse. Therefore, it's time to torture myself by beginning another Banlist Test. In...